Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BPMC, SLNO, CGON, XENE, VRNA, and represent 38.31% of Ally Bridge Group's stock portfolio.
- Added to shares of these 10 stocks: BPMC (+$15M), CGON (+$14M), VRNA (+$12M), MNMD (+$9.4M), JSPR (+$8.5M), KURA (+$7.8M), INSM (+$6.8M), DNTH (+$6.5M), LYRA (+$6.2M), LBPH (+$5.8M).
- Started 13 new stock positions in LBPH, MNMD, CGON, MRSN, BPMC, LYRA, JSPR, RAPT, INSM, DNTH. MRNS, VRNA, KURA.
- Reduced shares in these 10 stocks: Jasper Therapeutics (-$29M), ARGX (-$13M), Cymabay Therapeutics (-$12M), ITCI (-$10M), APLS (-$9.0M), MLTX (-$8.7M), AXSM (-$8.0M), Alpine Immune Sciences (-$6.8M), Ambrx Biopharma (-$5.5M), Harpoon Therapeutics.
- Sold out of its positions in Alpine Immune Sciences, AMLX, APLS, ARGX, AXSM, CMPX, Cymabay Therapeutics, Harpoon Therapeutics, ITCI, Jasper Therapeutics. MDVLQ, MLTX, Ambrx Biopharma.
- Ally Bridge Group was a net buyer of stock by $749k.
- Ally Bridge Group has $180M in assets under management (AUM), dropping by 7.19%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 22 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Blueprint Medicines (BPMC) | 8.5 | $15M | NEW | 161k | 94.86 |
|
| Soleno Therapeutics (SLNO) | 8.0 | $14M | +8% | 337k | 42.80 |
|
| Cg Oncology (CGON) | 7.8 | $14M | NEW | 320k | 43.90 |
|
| Xenon Pharmaceuticals (XENE) | 7.4 | $13M | +27% | 309k | 43.05 |
|
| Verona Pharma Sponsored Ads (VRNA) | 6.6 | $12M | NEW | 737k | 16.09 |
|
| Merus N V (MRUS) | 6.4 | $12M | -6% | 256k | 45.03 |
|
| Praxis Precision Medicines I (PRAX) | 5.4 | $9.7M | +126% | 160k | 61.02 |
|
| Mind Medicine Mindmed Com New (MNMD) | 5.2 | $9.4M | NEW | 1.0M | 9.40 |
|
| Avadel Pharmaceuticals Sponsored Adr | 5.1 | $9.2M | +57% | 547k | 16.89 |
|
| Geron Corporation (GERN) | 5.1 | $9.1M | -7% | 2.8M | 3.30 |
|
| Jasper Therapeutics Com New (JSPR) | 4.7 | $8.5M | NEW | 290k | 29.36 |
|
| Kura Oncology (KURA) | 4.3 | $7.8M | NEW | 365k | 21.33 |
|
| Insmed Com Par $.01 (INSM) | 3.8 | $6.8M | NEW | 250k | 27.13 |
|
| Dianthus Therapeutics (DNTH) | 3.6 | $6.5M | NEW | 217k | 30.00 |
|
| Olema Pharmaceuticals (OLMA) | 3.5 | $6.3M | -15% | 559k | 11.32 |
|
| Lyra Therapeutics (LYRA) | 3.5 | $6.2M | NEW | 1.0M | 6.22 |
|
| Longboard Pharmaceuticals In (LBPH) | 3.2 | $5.8M | NEW | 271k | 21.60 |
|
| Rapt Therapeutics (RAPT) | 2.1 | $3.8M | NEW | 420k | 8.98 |
|
| Mersana Therapeutics (MRSN) | 2.0 | $3.6M | NEW | 801k | 4.48 |
|
| Marinus Pharmaceuticals Com New (MRNS) | 2.0 | $3.6M | NEW | 395k | 9.04 |
|
| Promis Neurosciences Com New (PMN) | 1.1 | $2.0M | 1.1M | 1.91 |
|
|
| Context Therapeutics (CNTX) | 0.6 | $1.0M | 726k | 1.38 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2024 Q1 filed May 15, 2024
- Ally Bridge Group 2023 Q4 filed Feb. 14, 2024
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022
- Ally Bridge Group 2022 Q2 filed Aug. 15, 2022
- Ally Bridge Group 2022 Q1 filed May 16, 2022
- Ally Bridge Group 2021 Q4 filed Feb. 14, 2022
- Ally Bridge Group 2021 Q3 filed Nov. 15, 2021
- Ally Bridge Group 2021 Q2 filed Aug. 16, 2021
- Ally Bridge Group 2021 Q1 filed May 17, 2021
- Ally Bridge Group 2020 Q4 filed Feb. 16, 2021